Expression of survivin and clinical correlation in patients with breast cancer

Sohn, Doo Min; Kim, Sung Yong; Baek, Moo Jun; Lim, Cheol Wan; Lee, Min Hyuk; Cho, Moo Sik; Kim, Tae Yoon

doi:10.1016/j.biopha.2006.06.008

Cited by 52 publications

(40 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical samples, a high expression of survivin in malignant tumour cells has been reported to correlate with a shorter survival (Ferrandina et al, 2005;Lee et al, 2005;Atikcan et al, 2006;Sohn et al, 2006) and we also previously showed the survivin expression to be a significant prognostic marker for malignant gliomas Saito et al, 2007). Furthermore, survivin is also involved in radioresistance (Asanuma et al, 2002;Chakravarti et al, 2004;Rodel et al, 2005) and its suppression leads to an enhanced radiosensitivity in various malignant tumour cells (Pennati et al, 2003;Lu et al, 2004;Kappler et al, 2005).…”

mentioning

confidence: 66%

Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells

et al. 2008

View full text Add to dashboard Cite

Glioblastoma is characterised by invasive growth and a high degree of radioresistance. Survivin, a regulator of chromosome segregation, is highly expressed and known to induce radioresistance in human gliomas. In this study, we examined the effect of survivin suppression on radiosensitivity in malignant glioma cells, while focusing on centrosome aberration and chromosome instability (CIN). We suppressed survivin by small interfering RNA transfection, and examined the radiosensitivity using a clonogenic assay and a trypan blue exclusion assay in U251MG (p53 mutant) and D54MG (p53 wild type) cells. To assess the CIN status, we determined the number of centrosomes using an immunofluorescence analysis, and the centromeric copy number by fluorescence in situ hybridisation. As a result, the radiosensitisation differed regarding the p53 status as U251MG cells quickly developed extreme centrosome amplification ( ¼ CIN) and enhanced the radiosensitivity, while centrosome amplification and radiosensitivity increased more gradually in D54MG cells. TUNEL assay showed that survivin inhibition did not lead to apoptosis after irradiation. This cell death was accompanied by an increased degree of aneuploidy, suggesting mitotic cell death. Therefore, survivin inhibition may be an attractive therapeutic target to overcome the radioresistance while, in addition, proper attention to CIN (centrosome number) is considered important for improving radiosensitivity in human glioma.

show abstract

mentioning

confidence: 66%

Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells

et al. 2008

View full text Add to dashboard Cite

show abstract

“…We used the polyclonal antibody against full-length human survivin, as canine survivin has the same length and is 91.5% homologous to its human counterpart at the amino acid level (Uchide et al 2005). This antibody has been used in previous studies conducted in human medicine (Martinez et al 2004, Sohn et al 2006, Margulis et al 2007) as well as on canine tissues (Rankin et al 2008, Rhebun et al 2008, Bongiovanni et al 2009, Wimmershoff et al 2010, Bongiovanni et al 2012a. Recently, Wimmershoff et al (2010) confirmed that this polyclonal antibody is a reliable and sensitive tool for the detection of survivin in canine tissues.…”

Section: Discussionmentioning

confidence: 93%

Survivin expression in canine lymphomas in relation with proliferative markers

Sokołowska¹,

Urbańska²,

Gizinski³

et al. 2015

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

Survivin is a member of apoptosis inhibiting proteins family. Apart from its antiapoptotic activity it plays a critical role in regulating the cell cycle and mitosis. It is overexpressed in most human malignancies. While the prognostic significance of survivin expression is widely investigated in human non-Hodgkin's lymphomas, little is known about its expression in canine lymphomas. The aim of the study was to evaluate the expression of survivin in canine lymphomas in relation to proliferation markers (mitotic index and percentage of Ki67-positive cells). Survivin was found in all examined lymphomas belonging to 6 different morphological subtypes with nuclear immunoreactivity. In most of lymphomas (18/25) survivin expression ranged 10%-25% of positive cells. Only single cases had lower (0-10% positive cells, 1/25) or higher (25-50% and >50% positive cells, 5/25 and 1/25, respectively) index of survivin. Neither mitotic index nor proliferative index correlated with survivin expression when the values quantified randomly in whole specimens were compared. However, when survivin expression were quantified in selected tumor areas of low and high proliferation activity the high correlations between survivin expression and proliferation index were found. The results indicated that survivin is commonly expressed in canine lymphomas. Nuclear labelling together with the relation of its expression and proliferative activity in highly proliferative areas of neoplastic tissue suggest a potential role of survivin in cell cycle activation in canine lymphoma cells. However, further studies of the relation between expression of survivin and other proteins involved in cell cycle regulation are needed. Moreover, the results suggest that survivin may pose the therapeutic target in canine lymphomas.

show abstract

“…Although overexpression of survivin is associated with poor prognosis in most human cancers, the prognostic role of this protein is ambiguous in breast cancer patients [14,20,21]. Knowledge regarding the expression of the other IAP family members is limited, especially concerning the clinicopathological data of breast cancer.…”

mentioning

confidence: 99%

Expression of IAP family proteins and its clinical importance in breast cancer patients

Pluta¹,

Jeziorski²,

Cebula-Obrzut³

et al. 2015

neo

View full text Add to dashboard Cite

Inhibitor of apoptosis (IAP) family proteins is involved in mechanisms of resistance to apoptosis in various cancer cells. The aim of this study was to assess the expression of selected IAP proteins such as XIAP, cIAP-1, cIAP-2 and survivin in breast cancer patients and evaluates their relationship with the prognostic and predictive factors and their impact to overall survival (OS) and progression free survival (PFS). The study was conducted with the use of tissue samples prospectively collected from 92 previously untreated female breast cancer patients. The control encompassed 10 fibroadenoma patients. The expression of XIAP, cIAP-1, cIAP-2 and survivin was assessed using flow multicolor cytometry. XIAP expression was present in 99 % of the breast cancer patients (91/92) with the median expression 13.65% (range 1-66.8%). Expression of XIAP in breast cancer was significantly higher compared to the control group (p=0.006). Median expression of cIAP-1, cIAP-2 and survivin in the study group was 25.95% (range 0.8-83.7%), 16.7% (range 1-53.2%) and 4.6% (range 0-43%) respectively. In the rank Spearman test, strong correlations (p<0.001) were seen among the expressions of XIAP, cIAP-2 and survivin, in all combination. Additionally, week correlation between XIAP and cIAP-1 was observed (p=0.02). The median expression of XIAP and survivin was significantly higher in more advanced tumors (stages pT2/pT3 vs. pT1). The median PFS and OS in breast cancer group were 46.15 and 47.1 months respectively. No significant correlations were observed among expressions of IAP family proteins and survival. However, low expression of XIAP in breast cancer showed trend to longer PFS (p=0.08). XIAP, cIAP-1 cIAP-2 and survivin participate in antiapoptotic mechanisms in breast cancer and XIAP and survivin seem to have the most significant prognostic importance. Further studies are needed to establish more complete prognostic and predictive values of IAP family proteins in breast cancer patients.

show abstract

Expression of survivin and clinical correlation in patients with breast cancer

Cited by 52 publications

References 9 publications

Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells

Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells

Survivin expression in canine lymphomas in relation with proliferative markers

Expression of IAP family proteins and its clinical importance in breast cancer patients

Contact Info

Product

Resources

About